Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.
Also called NCT03862716
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 159 participants
- Registry
-
NCT03862716
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT03862716. Randomized; no masking; primary purpose treatment. Start 2019-04-23 (actual); primary completion 2022-06-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
- Acronym
- REMITiDegLira
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- IDegLira
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- Metformin
- Intervention (Behavioral)
- Lifestyle Therapy
- Lead sponsor
- Population Health Research Institute
- Collaborator
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03862716- Content hash
7ad0d2822a2c69375db7242ca13ab1a3a8ec95e6cb6a631d40f081027de323e3